BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 94.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 230,393 shares of the company’s stock after selling 4,011,993 shares during the period. HighTower Advisors LLC owned 0.12% of BridgeBio Pharma worth $11,967,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in BridgeBio Pharma by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 3,681,580 shares of the company’s stock valued at $158,991,000 after acquiring an additional 178,686 shares during the last quarter. Invesco Ltd. grew its position in shares of BridgeBio Pharma by 27.0% in the second quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock valued at $120,950,000 after purchasing an additional 594,902 shares in the last quarter. Norges Bank purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at approximately $84,488,000. Principal Financial Group Inc. increased its holdings in shares of BridgeBio Pharma by 23.0% in the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock valued at $65,829,000 after purchasing an additional 236,885 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in BridgeBio Pharma by 6.1% during the second quarter. American Century Companies Inc. now owns 1,090,134 shares of the company’s stock worth $47,072,000 after buying an additional 62,646 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results improve the commercial and regulatory outlook for BridgeBio’s achondroplasia program — a fundamental driver for longer‑term upside. PROPEL 3 Results
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and boosted its price target to $100 while maintaining a Buy — analyst upgrades can support buying interest and help re‑rate shares if fundamentals continue to improve. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst coverage remains constructive (multiple Buy/Overweight ratings and higher targets), which can amplify rallies following positive clinical/financial news. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this is the next near‑term catalyst that could drive volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to new hires (~76,701 shares aggregate) — modest ongoing share‑based comp that could be a small dilution factor to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer reported a small new 13F position (~7,845 shares) — modest institutional interest but not yet material to the register. Oppenheimer 13F
• Neutral Sentiment: Short‑interest reporting for Feb. 19 shows anomalous/zero values in the feed (likely a data/reporting glitch) — no clear evidence of a meaningful short squeeze or build from this item alone.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal W. Scott sold 10,000 shares and senior officers (CFO and CAO) also disclosed sales (CFO ~13,600 shares; CAO 510 shares) — concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Ongoing pattern of executive liquidity events highlighted in reporting — repeated insider selling can keep downward pressure on the stock until insiders demonstrate renewed accumulation. Insider/Sentiment Summary

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $68.14 on Friday. The firm has a market cap of $13.13 billion, a P/E ratio of -16.30 and a beta of 1.13. The firm’s 50 day moving average price is $75.52 and its 200-day moving average price is $63.98. BridgeBio Pharma, Inc. has a one year low of $28.33 and a one year high of $84.94.

Insider Transactions at BridgeBio Pharma

In related news, Director Randal W. Scott sold 10,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the transaction, the director owned 11,589 shares of the company’s stock, valued at approximately $874,505.94. This represents a 46.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total value of $1,016,192.00. Following the transaction, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 176,121 shares of company stock valued at $13,009,631 over the last three months. 18.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

BBIO has been the subject of several analyst reports. Leerink Partners upped their target price on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Truist Financial upped their price objective on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Oppenheimer raised their price objective on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Piper Sandler lifted their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Finally, Raymond James Financial set a $89.00 price target on shares of BridgeBio Pharma and gave the company an “outperform” rating in a research note on Thursday, February 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.